ADAMA Reports Fourth Quarter and Full Year 2023 Results
Management focus led to a significant improvement in cash flow despite challenging market conditions negatively impacting sales and profit
Fourth Quarter 2023 Highlights:
- Sales down 13% to
$1,136 million (-13% in RMB terms; -14% in CER[1] terms), mainly reflecting a 15% decrease in prices and a 1% increase in volumes - Adjusted EBITDA amounted to
$95 million vs.$129 million in Q4 2022 - Adjusted net loss of
$101 million ; Reported net loss of$79 million - Operating Cash Flow of
$293 million vs$352 million in Q4 2022 - Free Cash Flow of
$130 million vs$204 million in Q4 2022
Full Year 2023 Highlights:
- Sales down 16% to
$4,661 million (-12% in RMB terms; -15% in CER terms), mainly reflecting a 8% decrease in prices and a 7% decrease in volumes - Adjusted EBITDA amounted to
$407 million vs.$740 million in the full year of 2022 - Adjusted net loss of
$236 million ; Reported net loss of$225 million - Operating Cash Flow of
$356 million vs$106 million in 2022 - Free Cash Flow of -
$147 million vs -$417 million in 2022

"In addition to the significant improvement in cashflow, we improved the sales mix of higher margin products, reduced operating expenses and inventory. These, however, are only the first steps to ensure the Company is fully prepared to take advantage of anticipated market opportunities in 2024 and onwards. To fully respond to the long-term as well as short-term market challenges, we launched an intensive transformation plan aimed at improving the quality of the business and revaluing ADAMA. We will focus on winning in the largest growing segment of the market – the value innovation segment – with our outstanding pipeline of differentiated products powered by our proprietary formulation technologies. Coupled with resolute focus on improving our cost base and leveraging our strong commercial engine and customer driven culture, I am confident that we will succeed to revalue the Company going forward. I expect to share key milestones as the year progresses."
Table 1. Financial Performance Summary
USD (m) | As Reported | Adjustments | Adjusted | ||||||
Q4 2023 | Q4 2022 | % Change | Q4 2023 | Q4 2022 | Q4 2023 | Q4 2022 | % Change | ||
Revenues | 1,136 | 1,312 | (13 %) | - | - | 1,136 | 1,312 | (13 %) | |
Gross profit | 220 | 304 | (28 %) | 24 | 36 | 245 | 341 | (28 %) | |
% of sales | 19.4 % | 23.2 % | 21.5 % | 26.0 % | |||||
Operating income (loss) (EBIT) | (27) | 26 | 51 | 28 | 24 | 55 | (56 %) | ||
% of sales | (2.4 %) | 2.0 % | 2.1 % | 4.2 % | |||||
Loss before taxes | (42) | (20) | (23) | (18) | (65) | (39) | |||
% of sales | (3.7 %) | (1.6 %) | (5.7 %) | (2.9 %) | |||||
Net income (loss) | (79) | (22) | (22) | (19) | (101) | (42) | |||
% of sales | (6.9 %) | (1.7 %) | (8.9 %) | (3.2 %) | |||||
EPS | |||||||||
- USD | (0.0338) | (0.0096) | (0.0434) | (0.0178) | |||||
- RMB | (0.2418) | (0.0681) | (0.3099) | (0.1265) | |||||
EBITDA | 86 | 127 | (32 %) | 9 | 2 | 95 | 129 | (27 %) | |
% of sales | 7.5 % | 9.6 % | 8.3 % | 9.8 % | |||||
USD (m) | As Reported | Adjustments | Adjusted | ||||||
FY 2023 | FY 2022 | % Change | FY 2023 | FY 2022 | FY 2023 | FY 2022 | % Change | ||
Revenues | 4,661 | 5,570 | (16 %) | - | - | 4,661 | 5,570 | (16 %) | |
Gross profit | 968 | 1,403 | (31 %) | 91 | 162 | 1,060 | 1,565 | (32 %) | |
% of sales | 20.8 % | 25.1 % | 22.7 % | 28.1 % | |||||
Operating income (EBIT) | 62 | 389 | (84 %) | 79 | 68 | 141 | 458 | (69 %) | |
% of sales | 1.3 % | 7.0 % | 3.0 % | 8.2 % | |||||
Income (loss) before taxes | (197) | 118 | (10) | 25 | (207) | 144 | |||
% of sales | (4.2 %) | 2.1 % | (4.4 %) | 2.6 % | |||||
Net income (loss) | (225) | 96 | (11) | 21 | (236) | 118 | |||
% of sales | (4.8 %) | 1.7 % | (5.1 %) | 2.1 % | |||||
EPS | |||||||||
- USD | (0.0964) | 0.0413 | (0.1013) | 0.0505 | |||||
- RMB | (0.6893) | 0.2616 | (0.7260) | 0.3177 | |||||
EBITDA | 400 | 731 | (45 %) | 7 | 9 | 407 | 740 | (45 %) | |
% of sales | 8.6 % | 13.1 % | 8.7 % | 13.3 % | |||||
Notes:
- "As Reported" denotes the Company's financial statements according to the Accounting Standards for Business Enterprises and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the Chinese Ministry of Finance (the "MoF) (collectively referred to as "ASBE"). Note that in the reported financial statements, according to the ASBE guidelines [IAS 37], certain items (specifically certain transportation costs and certain idleness charges) are classified under COGS. Please see the appendix to this release for further information.
- Relevant income statement items contained in this release are also presented on an "Adjusted" basis, which exclude items that are of a transitory or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company's management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers. A detailed summary of these adjustments appears in the appendix below.
- The number of shares used to calculate both basic and diluted earnings per share in both Q4 & FY 2023 and 2022 is 2,329.8 million shares.
- In this table and all tables in this release numbers may not sum due to rounding.
The General Crop Protection (CP) Market Environment[2]
Key commodity crop prices declined substantially during 2023 as weather conditions normalized and the global crop supply situation improved. However, key commodity crop prices were still relatively high through 2023, supporting planted area and investment in crops, leading to healthy demand, at the farmer level, of crop inputs, including crop protection products. However, due to very high channel inventory across all geographies, channel demand was weak during 2023. The high interest rate environment coupled with low prices of active ingredient from
Update on the War Situation in
ADAMA is headquartered in
Update on Impact of Shipping Obstructions
In
As of the date of publication of this report, shipping time and costs have increased significantly, mainly in the Asia-Pacific Israel route in comparison to before
Turnaround Plan
As a result of the challenges in the crop protection industry in 2023, as described above, the Company has initiated a plan to revalue ADAMA through improving the quality of the business to turnaround the Company.
This turnaround plan has three main pillars:
(i) Market repositioning - focusing on Value Innovation, the market space where innovation is served not through new active ingredients but by innovation at the product level using existing active ingredients enhanced by proprietary formulations;
(ii) Optimizing ADAMA's product portfolio to focus on quality of business through strategic crop segments within the customer market segment of Value Innovation;
(iii) Improving ADAMA's cost of goods and operating expenses.
As part of this plan, the Company has initiated organizational changes to improve efficiencies that also include adjusting the workforce. These have begun with streamlining the Company's senior management team to ensure efficient decision making, while changes have also been made in the Company's R&D, marketing commercial and operations, all in order to support the Company in capturing the opportunity of Value Innovation.
Sustainability
In ADAMA's 2022 Environmental, Social, and Corporate Governance (ESG) report, published
As of the end of 2023, ADAMA is in line with achieving this target.
Sustainability in Products:
- In 2023 the first product based on Sesgama™ was launched. Sesgama™ is ADAMA's proprietary formulation technology platform for high-load and other challenging formulations, enabling less use of co-formulants, transport and packaging materials per acre treated with a resulting improved product sustainability profile. The product launched was the herbicide FullScript™, launched in the US.
- During 2023 ADAMA continued to register and launch products based on its proprietary Asorbital® formulation technology platform a unique formulation that improves the leaf penetration and systemic movement of the Active Ingredient in the plant, while minimizing environmental impact. This technology provides greater efficacy and sustainability and can be used to reduce application rates.
- Expanded use of containers with reduced environmental impact – Containers that have been redesigned to a rectangular shape from a cylinder allow for product to be placed more densely on pallets and trucks, enabling a 45% increase in product packed, reducing transportation needs and associated carbon emissions, as well as comprise 10% less plastic. Following a successful launch in
India , this design is expected to be launched in additional geographies bringing a reduction of 17.2% in GHG emissions, eliminating the release of up to 340 metric tons of CO2e into the atmosphere annually.
Sustainability in manufacturing:
- Shift of Company vehicles to electrical – during 2023 52% of ADAMA's forklifts at its manufacturing sites in
Israel and 42% of its private cars inIsrael transitioned to electrical. This trend will continue in 2024, aiming to double the number of electrical forklifts and increase by 20% the number of electrical private cars. The electrical forklifts saved 160,000 liters of diesel in 2023. - Recycling hazardous waste back to raw materials – ADAMA collaborates with inhouse or external recycling companies to reuse/recycle 13,817 tons of hazardous wastes back to raw materials utilizing by its own operations or other industries. In
Israel , ADAMA operates two plastic recycling centers at its largest formulation sites, Agan andBeer Sheva . These centers clean contaminated plastic packing products, allowing the use of the plastic to produce pipes in the construction and communication sectors.
Portfolio Development Update
Product Launches, Registrations & Formulation Mastery Update:
During 2023 ADAMA continued to register and launch multiple new products in markets across the globe, adding on to its differentiated product portfolio. New Product Introductions (NPI) percentage out of the full year sales of 2023 reached 22%, referring to products launched over the past 5 years. Differentiated products include products that are based on recently off-patented active ingredients (AI's) that have been classified as high commercial potential - "Core Leap" AI's, and products that are based on unique proprietary formulations, products with more than one mode of action, and biologicals.
Launch of 11 new differentiated products during 2023 in select countries including the following products during the fourth quarter:
- Continued roll out in
Europe of ADAMA's prothioconazole products based on Asorbital® formulation mastery technology platform, including Maganic® and Forapro® inSweden - Launch in
India of Trassid™, a unique insecticide designed to offer a superior control in high value crops. Trassid™ represents ADAMA's first active ingredient Spinetoram based solution - Launch in
Peru of Actavan®, a bio- fungicide for use in fruits. Actavan® was developed in collaboration with theNew Zealand company Waikaitu Ltd. Actavan® is an addition to ADAMA's biological product portfolio in LATAM
Registration of 20 new differentiated products during 2023 in select countries including the following products during the fourth quarter:
- Registration of prothioconazole based products, part of ADAMA's comprehensive portfolio of innovative solutions for cereal fungicides in
Europe , including:
- Forapro® inPoland , powered by ADAMA's proprietary Asorbital® Formulation Technology
- Soratel® inLatvia , powered by ADAMA's proprietary Asorbital® Formulation Technology
- Maxentis® inIreland , a dual mode broad spectrum fungicide - Registration of two insecticides based on "Core Leap" AI, Chlorantraniliprole (CTPR), RYNO-A® in
Canada and Cosayr® inSouth Korea - Registration in
Hungary of Actavan®, a bio- fungicide for use in fruits. Actavan® was developed in collaboration with theNew Zealand company Waikaitu Ltd. - Registration in
Canada of Outshine All In™ and ForceFighter All In™, two triple mode-of-action herbicides
Select patent granted during the fourth quarter of 2023 includes:
- Patent granted in
India for ADAMA's unique Granular Formulation of the product Barroz® a dual mode insecticide for use in rice.
Financial Highlights
Revenues in the fourth quarter declined by approximately 13% (-13% in RMB terms; -14% in CER terms) to
These results brought the revenues in the full year of 2023 to
Table 2. Regional Sales Performance
Q4 2023 $m | Q4 2022 $m | Change USD | Change CER | FY 2023 $m | FY 2022 $m | Change USD | Change CER | ||
241 | 301 | (20 %) | (20 %) | 1,240 | 1,352 | (8 %) | (5 %) | ||
252 | 291 | (14 %) | (14 %) | 820 | 1,027 | (20 %) | (20 %) | ||
379 | 431 | (12 %) | (15 %) | 1,292 | 1,592 | (19 %) | (22 %) | ||
264 | 288 | (8 %) | (8 %) | 1,308 | 1,598 | (18 %) | (14 %) | ||
Of which | 97 | 130 | (25 %) | (24 %) | 550 | 735 | (25 %) | (21 %) | |
Total | 1,136 | 1,312 | (13 %) | (14 %) | 4,661 | 5,570 | (16 %) | (15 %) |
Notes:
CER: Constant Exchange Rates
Numbers may not sum due to rounding
* 2022 denote proforma sales. As of 2023, the
In the US Ag market sales in the fourth quarter and the twelve-month period reflected low demand, weak pricing and strong competition due to high inventory levels at manufactures. While inventory levels in the channel are steadily declining, manufactures are still holding high inventory levels leading to strong competition, thus pricing is still not presenting a recovery with the market leaning into just-in-time purchasing patterns.
ADAMA reached record sales in
Such differentiated products included Almada® (fungicide against soybean rust), Forasteiro® (herbicide for pasture) and Araddo® (herbicide for soybean and cotton).
In the rest of LATAM the sales in the fourth quarter recovered and increased with the normalization of channel inventories in most countries while sales remained flat in the full year of 2023, mainly impacted by pricing of commoditized products. It is noteworthy that the Company gained market share in key countries Argentina,
In
In the Pacific region, sales in the full year and fourth quarter were impacted by high channel inventories and pricing pressure, combined with just in time purchasing patterns. In
Sales in
Sales in the wider APAC region continued to experience pricing pressure, particularly from commoditized products. Despite this, particularly noteworthy was the performance of the Company's sales in
Gross Profit reported in the fourth quarter reached
Adjustments to reported results: The adjusted gross profit includes reclassification of all inventory impairment, taxes and surcharge and excludes certain transportation costs (classified under operating expenses).
Adjusted gross profit in the fourth quarter reached
The decline in the gross profit in the fourth quarter and full year of 2023 was mainly due to the weak pricing, as described above, moderated by the positive impact of new inventory sold, priced at market levels and an improvement in the sales mix of higher margin products, following management focus on the quality of business. Exchange rates had an adverse impact in the full year and a positive impact in the fourth quarter, in comparison to the same periods in 2022.
Operating expenses reported in the fourth quarter and full year of 2023 were
Adjustments to reported results: please refer to the explanation regarding adjustments to the gross profit in respect to certain transportation costs, taxes and surcharges and inventory impairment.
Additionally, the Company recorded certain non-operational items within its reported operating expenses amounting to
Adjusted operating expenses in the fourth quarter and full year were
The operating expenses were lower in the fourth quarter and full year of 2023 mainly due to OPEX management measures taken by the Company to address the market conditions, a reduction in performance-based compensation, lower transportation and logistics costs and the positive impact of exchange rates. Additionally, in the full year of 2022 the Company recorded a provision for doubtful debts in
Operating income (loss) reported in the fourth quarter reached a loss of
Adjusted operating income in the fourth quarter reached
EBITDA reported in the fourth quarter amounted to
Excluding the impact of the abovementioned non-operational items, adjusted EBITDA in the fourth quarter amounted to
Adjusted financial expenses amounted to
The lower financial expenses in the quarter were due to lower bond interest following the installment payment of bond principal in
Adjusted taxes on income in the fourth quarter amounted to tax expenses of
Despite reaching losses before tax, the Company recorded tax expenses in the fourth quarter and in the full year of 2023 mainly because the losses were primarily incurred by subsidiaries with relatively lower tax rates, while some of them did not create deferred tax assets on the losses. On the other hand, the subsidiaries that generated profit have a higher tax rate. In comparison, in 2022, the Company recognized a high deferred tax asset, related to inter-group sales and one-time tax expense electing to apply for temporary relief available in 2022 and in order to reduce tax exposure in
Net loss reported in the fourth quarter was
After reflecting the impact of the abovementioned extraordinary and non-operational charges, adjusted net loss in the fourth quarter was
Trade working capital as of
Cash Flow: Operating cash flow of
Net cash used in investing activities was
Free cash flow of
Table 3. Revenues by operating segment
Sales by segment | ||||||||
Q4 2023 USD (m) | % | Q4 2022 USD (m) | % | FY 2023 USD (m) | % | FY 2022 USD (m) | % | |
Crop Protection | 1,035 | 91 % | 1,207 | 92 % | 4,268 | 92 % | 5,032 | 90 % |
Intermediates and Ingredients | 102 | 9 % | 105 | 8 % | 393 | 8 % | 538 | 10 % |
Total | 1,136 | 100 % | 1,312 | 100 % | 4,661 | 100 % | 5,570 | 100 % |
Sales by product category | ||||||||
Q4 2023 USD (m) | % | Q4 2022 USD (m) | % | FY 2023 USD (m) | % | FY 2022 USD (m) | % | |
Herbicides | 438 | 39 % | 546 | 42 % | 1,969 | 42 % | 2,479 | 45 % |
Insecticides | 345 | 30 % | 382 | 29 % | 1,334 | 29 % | 1,505 | 27 % |
Fungicides | 251 | 22 % | 279 | 21 % | 965 | 21 % | 1,048 | 19 % |
Intermediates and Ingredients | 102 | 9 % | 105 | 8 % | 393 | 8 % | 538 | 10 % |
Total | 1,136 | 100 % | 1,312 | 100 % | 4,661 | 100 % | 5,570 | 100 % |
Notes:
- The sales split by product category is provided for convenience purposes only and is not representative of the way the Company is managed or in which it makes its operational decisions.
- Numbers may not sum due to rounding.
Further Information
All filings of the Company, together with a presentation of the key financial highlights of the period, can be accessed through the Company website at www.adama.com.
About ADAMA
ADAMA Ltd. is a global leader in crop protection, providing practical solutions to farmers across the world to combat weeds, insects and disease. Our culture empowers ADAMA's people to actively listen to farmers and ideate from the field. ADAMA's diverse portfolio of existing active ingredients, coupled with its leading formulation capabilities and proprietary formulation technology platforms, uniquely position the company to develop high-quality, innovative and sustainable products, to address the many challenges farmers and customers face today. ADAMA serves customers in over 100 countries globally. For more information, visit us at www.ADAMA.com and follow us on Twitter® at @ADAMAAgri.
Contact:
Global Investor Relations
[email protected]
China Investor Relations
[email protected]
Abridged Adjusted Consolidated Financial Statements
The following abridged consolidated financial statements and notes have been prepared as described in Note 1 in this appendix. While prepared based on the principles of Chinese Accounting Standards (ASBE), they do not contain all of the information which either ASBE or IFRS would require for a complete set of financial statements, and should be read in conjunction with the consolidated financial statements of both ADAMA Ltd. and Adama Agricultural Solutions Ltd. as filed with the
Relevant income statement items contained in this release are also presented on an "Adjusted" basis, which exclude items that are of a one-time or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company's management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers.
Abridged Consolidated Income Statement for the Fourth Quarter | ||||
Adjusted[3] | Q4 2023 USD (m) | Q4 2022 USD (m) | Q4 2023 RMB (m) | Q4 2022 RMB (m) |
Revenues | 1,136 | 1,312 | 8,119 | 9,304 |
Cost of Sales | 882 | 962 | 6,304 | 6,823 |
Other costs | 9 | 9 | 67 | 66 |
Gross profit | 245 | 341 | 1,748 | 2,415 |
% of revenue | 21.5 % | 26.0 % | 21.5 % | 26.0 % |
Selling & Distribution expenses | 160 | 198 | 1,145 | 1,402 |
General & Administrative expenses | 40 | 60 | 283 | 426 |
Research & Development expenses | 15 | 23 | 110 | 162 |
Other operating expenses | 5 | 5 | 35 | 36 |
Total operating expenses | 220 | 286 | 1,574 | 2,026 |
% of revenue | 19.4 % | 21.8 % | 19.4 % | 21.8 % |
Operating income (EBIT) | 24 | 55 | 174 | 389 |
% of revenue | 2.1 % | 4.2 % | 2.1 % | 4.2 % |
Financial expenses | 89 | 94 | 636 | 664 |
Loss before taxes | (65) | (39) | (462) | (274) |
Taxes on Income | 36 | 3 | 260 | 21 |
Net Income | (101) | (42) | (722) | (295) |
% of revenue | (8.9 %) | (3.2 %) | (8.9 %) | (3.2 %) |
Adjustments | (22) | (19) | (159) | (136) |
Reported Net income | (79) | (22) | (563) | (159) |
% of revenue | (6.9 %) | (1.7 %) | (6.9 %) | (1.7 %) |
Adjusted EBITDA | 95 | 129 | 676 | 913 |
% of revenue | 8.3 % | 9.8 % | 8.3 % | 9.8 % |
Adjusted EPS[4] – Basic | (0.0434) | (0.0178) | (0.3099) | (0.1265) |
– Diluted | (0.0434) | (0.0178) | (0.3099) | (0.1265) |
Reported EPS[5] – Basic | (0.0338) | (0.0096) | (0.2418) | (0.0681) |
– Diluted | (0.0338) | (0.0096) | (0.2418) | (0.0681) |
Abridged Consolidated Income Statement for the Full Year | ||||
Adjusted[5] | FY 2023 USD (m) | FY 2022 USD (m) | FY 2023 RMB (m) | FY 2022 RMB (m) |
Revenues | 4,661 | 5,570 | 32,779 | 37,382 |
Cost of Sales | 3,549 | 3,966 | 24,977 | 26,633 |
Other costs | 52 | 40 | 366 | 267 |
Gross profit | 1,060 | 1,565 | 7,436 | 10,482 |
% of revenue | 22.7 % | 28.1 % | 22.7 % | 28.0 % |
Selling & Distribution expenses | 700 | 805 | 4,928 | 5,409 |
General & Administrative expenses | 145 | 206 | 1,018 | 1,388 |
Research & Development expenses | 69 | 86 | 483 | 578 |
Other operating expenses | 5 | 11 | 35 | 68 |
Total operating expenses | 918 | 1,107 | 6,464 | 7,442 |
% of revenue | 19.7 % | 19.9 % | 19.7 % | 19.9 % |
Operating income (EBIT) | 141 | 458 | 973 | 3,040 |
% of revenue | 3.0 % | 8.2 % | 3.0 % | 8.1 % |
Financial expenses | 348 | 314 | 2,451 | 2,126 |
Income before taxes | (207) | 144 | (1,479) | 914 |
Taxes on Income | 30 | 26 | 213 | 174 |
Net Income | (236) | 118 | (1,691) | 740 |
% of revenue | (5.1 %) | 2.1 % | (5.2 %) | 2.0 % |
Adjustments | (11) | 21 | (85) | 131 |
Reported Net income | (225) | 96 | (1,606) | 609 |
% of revenue | (4.8 %) | 1.7 % | (4.9 %) | 1.6 % |
Adjusted EBITDA | 407 | 740 | 2,844 | 4,940 |
% of revenue | 8.7 % | 13.3 % | 8.7 % | 13.2 % |
Adjusted EPS[6] – Basic | (0.1013) | 0.0505 | (0.7260) | 0.3177 |
– Diluted | (0.1013) | 0.0505 | (0.7260) | 0.3177 |
Reported EPS7 – Basic | (0.0964) | 0.0413 | (0.6893) | 0.2616 |
– Diluted | (0.0964) | 0.0413 | (0.6893) | 0.2616 |
Abridged Consolidated Balance Sheet | ||||
2023 USD (m) | 2022 USD (m) | 2023 RMB (m) | 2022 RMB (m) | |
Assets | ||||
Current assets: | ||||
Cash at bank and on hand | 689 | 616 | 4,881 | 4,291 |
Bills and accounts receivable | 1,306 | 1,433 | 9,251 | 9,980 |
Inventories | 1,848 | 2,430 | 13,089 | 16,927 |
Other current assets, receivables and prepaid expenses | 339 | 279 | 2,401 | 1,943 |
Total current assets | 4,182 | 4,758 | 29,622 | 33,141 |
Non-current assets: | ||||
Fixed assets, net | 1,772 | 1,711 | 12,547 | 11,914 |
Rights of use assets | 88 | 80 | 625 | 556 |
Intangible assets, net | 1,457 | 1,457 | 10,320 | 10,148 |
Deferred tax assets | 226 | 193 | 1,602 | 1,347 |
Other non-current assets | 97 | 126 | 690 | 875 |
Total non-current assets | 3,640 | 3,567 | 25,784 | 24,840 |
Total assets | 7,823 | 8,325 | 55,406 | 57,980 |
Liabilities | ||||
Current liabilities: | ||||
Loans and credit from banks and other lenders | 1,134 | 805 | 8,031 | 5,605 |
Bills and accounts payable | 743 | 1,241 | 5,263 | 8,642 |
Other current liabilities | 791 | 929 | 5,600 | 6,468 |
Total current liabilities | 2,668 | 2,974 | 18,894 | 20,715 |
Long-term liabilities: | ||||
Loans and credit from banks and other lenders | 407 | 526 | 2,886 | 3,663 |
Debentures | 977 | 1,056 | 6,919 | 7,354 |
Deferred tax liabilities | 42 | 45 | 297 | 316 |
Employee benefits | 95 | 114 | 672 | 792 |
Other long-term liabilities | 538 | 290 | 3,813 | 2,017 |
Total long-term liabilities | 2,060 | 2,030 | 14,587 | 14,141 |
Total liabilities | 4,727 | 5,005 | 33,481 | 34,856 |
Equity | ||||
Total equity | 3,096 | 3,320 | 21,924 | 23,125 |
Total liabilities and equity | 7,823 | 8,325 | 55,406 | 57,980 |
Abridged Consolidated Cash Flow Statement for the Fourth Quarter | ||||
Q4 2023 | Q4 2022 | Q4 2023 | Q4 2022 | |
Cash flow from operating activities: | ||||
Cash flow from operating activities | 293 | 352 | 2,092 | 2,499 |
Cash flow from operating activities | 293 | 352 | 2,092 | 2,499 |
Investing activities: | ||||
Acquisitions of fixed and intangible assets | (93) | (99) | (663) | (699) |
Net cash received from disposal of fixed assets, intangible assets and others | 0 | 2 | 3 | 13 |
Other investing activities | (16) | 0 | (115) | 2 |
Cash flow used for investing activities | (108) | (96) | (775) | (684) |
Financing activities: | ||||
Receipt of loans from banks and other lenders | 203 | 79 | 1,473 | 559 |
Repayment of loans from banks and other lenders | (308) | (142) | (2,202) | (1,006) |
Interest payment and other | (55) | (53) | (392) | (379) |
Other financing activities | (76) | (48) | (541) | (336) |
Cash flow used for financing activities | (235) | (164) | (1,662) | (1,163) |
Effects of exchange rate movement on cash and cash equivalents | 1 | 2 | (79) | (70) |
Net change in cash and cash equivalents | (50) | 94 | (423) | 582 |
Cash and cash equivalents at the beginning of the period | 736 | 513 | 5,281 | 3,643 |
Cash and cash equivalents at the end of the period | 686 | 607 | 4,857 | 4,225 |
Free Cash Flow | 130 | 204 | 989 | 1,445 |
Abridged Consolidated Cash Flow Statement for the Full Year | ||||
FY 2023 | FY 2022 | FY 2023 | FY 2022 | |
Cash flow from operating activities: | ||||
Cash flow from operating activities | 356 | 106 | 2,618 | 941 |
Cash flow from operating activities | 356 | 106 | 2,618 | 941 |
Investing activities: | ||||
Acquisitions of fixed and intangible assets | (337) | (397) | (2,370) | (2,667) |
Net cash received from disposal of fixed assets, intangible assets and others | 6 | 13 | 40 | 85 |
Acquisition of subsidiaries | (22) | 0 | (148) | 0 |
Other investing activities | 13 | (12) | 90 | (78) |
Cash flow used for investing activities | (339) | (396) | (2,388) | (2,660) |
Financing activities: | ||||
Receipt of loans from banks and other lenders | 1,004 | 669 | 7,030 | 4,468 |
Repayment of loans from banks and other lenders | (589) | (342) | (4,176) | (2,331) |
Interest payment and other | (176) | (137 | (1,244) | (933) |
Dividends to shareholders | (9) | (3) | (63) | (19) |
Other financing activities | (167) | (187) | (1,173) | (1,242) |
Cash flow used for financing activities | 63 | (0) | 374 | (56) |
Effects of exchange rate movement on cash and cash equivalents | 0 | (7) | 28 | 241 |
Net change in cash and cash equivalents | 79 | (297) | 632 | (1,534) |
Cash and cash equivalents at the beginning of the period | 607 | 903 | 4,225 | 5,759 |
Cash and cash equivalents at the end of the period | 686 | 607 | 4,857 | 4,225 |
Free Cash Flow | (147) | (417) | (923) | (2,593) |
Notes to Abridged Consolidated Financial Statements
Note 1: Basis of preparation
Basis of presentation and accounting policies: The abridged consolidated financial statements for the quarters ended
The Company has adopted the Accounting Standards for Business Enterprises (ASBE) issued by the Ministry of Finance (the "MoF") and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the MoF (collectively referred to as "ASBE").
The abridged consolidated financial statements contained in this release are presented in both Chinese Renminbi (RMB), as the Company's shares are traded on the Shenzhen Stock Exchange, as well as in
The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated.
Note 2: Abridged Financial Statements
For ease of use, the financial statements shown in this release have been abridged as follows:
Abridged Consolidated Income Statement:
- "Gross profit" in this release is revenue less costs of goods sold, taxes and surcharges, inventory impairment and other idleness charges (in addition to those already included in costs of goods sold); part of the idleness charges is removed in the Adjusted financial statements
- "Other operating expenses" includes impairment losses (not including inventory impairment); gain (loss) from disposal of assets and non-operating income and expenses
- "Operating expenses" in this release differ from those in the formally reported financial statements in that certain transportation costs have been reclassified from COGS to Operating Expenses.
- "Financial expenses" includes net financing expenses and gains/losses from changes in fair value.
Abridged Consolidated Balance Sheet:
- "Other current assets, receivables and prepaid expenses" includes financial assets held for trading; financial assets in respect of derivatives; prepayments; other receivables; and other current assets
- "Fixed assets, net" includes fixed assets and construction in progress
- "Intangible assets, net" includes intangible assets and goodwill
- "Other non-current assets" includes other equity investments; long-term equity investments; long-term receivables; investment property; and other non-current assets
- "Loans and credit from banks and other lenders" includes short-term loans and non-current liabilities due within one year
- "Other current liabilities" includes financial liabilities in respect of derivatives; payables for employee benefits, taxes, interest, dividends and others; advances from customers and other current liabilities
- "Other long-term liabilities" includes long-term payables, provisions, deferred income and other non-current liabilities
Income Statement Adjustments
Q4 2023 USD (m) | Q4 2022 USD (m) | Q4 2023 RMB (m) | Q4 2022 RMB (m) | |
Reported Net Income (Loss) | (79) | (22) | (563) | (159) |
Adjustments to COGS & Operating Expenses: | ||||
1. Amortization of acquisition-related PPA and other acquisition related costs | 4 | 5 | 28 | 33 |
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina- | 5 | 6 | 35 | 42 |
3. Upgrade & Relocation related costs | 1 | 2 | 6 | 13 |
4. Incentive plans | (1) | 1 | (4) | 8 |
5. ASBEs classifications COGS impact | (22) | (34) | (158) | (239) |
6. ASBEs classifications OPEX impact | 22 | 34 | 158 | 239 |
7. Measures to improve efficiencies | 9 | 0 | 66 | 0 |
8. Fixed asset impairment in subsidiaries | 33 | 15 | 237 | 106 |
Total Adjustments to Operating Income (EBIT) | 51 | 28 | 367 | 202 |
Total Adjustments to EBITDA | 9 | 2 | 63 | 16 |
Adjustments to Financing Expenses: | ||||
9. Non-cash adjustment related to put option revaluation | (54) | (47) | (387) | (335) |
10. Release of holdback due to subsidiary | (17) | 0 | (123) | 0 |
Other financing expenses | (3) | 1 | (19) | 4 |
Adjustments to Taxes: | ||||
Taxes impact | (0) | 1 | (3) | 6 |
Total adjustments to Net Income | (22) | (19) | (159) | (136) |
Adjusted Net Income (Loss) | (101) | (42) | (722) | (295) |
FY 2023 USD (m) | FY 2022 USD (m) | FY 2023 RMB (m) | FY 2022 RMB (m) | |
Reported Net Income (Loss) | (225) | 96 | (1,606) | 609 |
Adjustments to COGS & Operating Expenses: | ||||
1. Amortization of acquisition-related PPA and other acquisition related costs | 17 | 20 | 116 | 137 |
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina- | 20 | 23 | 143 | 154 |
3. Upgrade & Relocation related costs | 3 | 7 | 22 | 49 |
4. Incentive plans | (3) | 3 | (21) | 18 |
5. ASBEs classifications COGS impact | (87) | (150) | (610) | (1,005) |
6. ASBEs classifications OPEX impact | 87 | 150 | 610 | 1,005 |
7. Measures to improve efficiencies | 9 | 0 | 66 | 0 |
8. Fixed asset impairment in subsidiaries | 33 | 15 | 237 | 106 |
Total Adjustments to Operating Income (EBIT) | 79 | 68 | 562 | 465 |
Total Adjustments to EBITDA | 7 | 9 | 53 | 59 |
Adjustments to Financing Expenses: | ||||
9. Non-cash adjustment related to put option revaluation | (61) | (47) | (438) | (335) |
10. Release of holdback due to subsidiary | (17) | 0 | (123) | 0 |
Other financing expenses | (11) | 4 | (75) | 27 |
Adjustments to Taxes | ||||
Taxes impact | 2 | 4 | 12 | 26 |
Total adjustments to Net Income | (11) | 21 | (85) | 131 |
Adjusted Net Income (Loss) | (236) | 118 | (1,691) | 740 |
Notes:
1. Amortization of acquisition-related PPA and other acquisition related costs:
a. Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash): Under ASBE, since the third combined reporting for Q3 2017, the Company has inherited the historical "legacy" amortization charge that ChemChina previously was incurring in respect of its acquisition of Solutions in 2011. This amortization is done in a linear manner on a quarterly basis, most of which will have been completed by the end of 2020.
b. Amortization of acquisition-related PPA (non-cash) and other acquisition-related costs: Related mainly to the non-cash amortization of intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired, as well as other M&A-related costs.
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash): The proceeds from the Divestment of crop protection products in connection with the approval by the EU Commission of the acquisition of Syngenta by ChemChina, net of taxes and transaction expenses, were paid to Syngenta in return for the transfer of a portfolio of products in
3.Upgrade & manufacturing facilities relocation-related costs: These charges relate to Upgrade & Relocation programs in
4. Incentive plans: ADAMA granted certain of its employees, a long-term incentive (LTI) in the form of 'phantom' awards linked to the Company's share price. As such, the Company records an expense, or recognizes income, depending on the fluctuation in the Company's share price, regardless of award exercises. To neutralize the impact of such share price movements on the measurement of the Company's performance and expected employee compensation and to reflect the existing phantom awards, in the Company's adjusted financial performance, the LTI is presented on an equity-settled basis in accordance with the value of the existing plan at the grant date.
5. ASBEs classifications COGS impact: according to the ASBE guidelines [IAS 37], certain items (specifically certain transportation costs) are classified under COGS.
6. ASBEs classifications OPEX impact: according to the ASBE guidelines [IAS 37], certain items (specifically certain transportation costs) are classified under COGS.
7. Measures to improve efficiencies – ADAMA recorded costs due to certain measures initiated to improve efficiencies mainly personnel changes.
Exchange Rate Data for the Company's Principal Functional Currencies | |||||||||||
Q4 Average | FY Average | ||||||||||
2023 | 2022 | Change | 2023 | 2022 | Change | 2023 | 2022 | Change | |||
EUR/USD | 1.106 | 1.067 | 3.7 % | 1.076 | 1.019 | 5.6 % | 1.081 | 1.052 | 2.8 % | ||
USD/BRL | 4.841 | 5.218 | 7.2 % | 4.953 | 5.256 | 5.8 % | 4.995 | 5.165 | 3.3 % | ||
USD/PLN | 3.935 | 4.402 | 10.6 % | 4.107 | 4.646 | 11.6 % | 4.204 | 4.458 | 5.7 % | ||
USD/ZAR | 18.563 | 16.949 | (9.5 %) | 18.744 | 17.618 | (6.4 %) | 18.446 | 16.367 | (12.7 %) | ||
AUD/USD | 0.682 | 0.680 | 0.4 % | 0.651 | 0.657 | (0.9 %) | 0.664 | 0.694 | (4.3 %) | ||
GBP/USD | 1.274 | 1.204 | 5.8 % | 1.240 | 1.171 | 5.9 % | 1.243 | 1.234 | 0.7 % | ||
USD/ILS | 3.627 | 3.519 | (3.1 %) | 3.819 | 3.493 | (9.3 %) | 3.687 | 3.358 | (9.8 %) | ||
USD L 3M | 5.33 % | 4.77 % | 0.56 bp | 5.38 % | 4.51 % | 0.87 bp | 5.38 % | 2.41 % | 2.97 bp | ||
Q4 Average | FY Average | ||||||||||
2023 | 2022 | Change | 2023 | 2022 | Change | 2023 | 2022 | Change | |||
USD/RMB | 7.083 | 6.965 | 1.7 % | 7.146 | 7.092 | 0.8 % | 7.042 | 6.721 | 4.8 % | ||
EUR/RMB | 7.834 | 7.428 | 5.5 % | 7.686 | 7.225 | 6.4 % | 7.614 | 7.071 | 7.7 % | ||
RMB/BRL | 0.684 | 0.749 | 8.8 % | 0.693 | 0.741 | 6.5 % | 0.709 | 0.768 | 7.7 % | ||
RMB/PLN | 0.556 | 0.632 | 12.1 % | 0.575 | 0.655 | 12.3 % | 0.597 | 0.663 | 10.0 % | ||
RMB/ZAR | 2.621 | 2.434 | (7.7 %) | 2.623 | 2.484 | (5.6 %) | 0.597 | 2.435 | 75.5 % | ||
AUD/RMB | 4.834 | 4.733 | 2.1 % | 4.650 | 4.656 | (0.1 %) | 4.677 | 4.663 | 0.3 % | ||
GBP/RMB | 9.024 | 8.387 | 7.6 % | 8.864 | 8.307 | 6.7 % | 8.752 | 8.292 | 5.6 % | ||
RMB/ILS | 0.512 | 0.505 | (1.3 %) | 0.534 | 0.492 | (8.5 %) | 0.524 | 0.500 | (4.8 %) | ||
RMB L 3M | 2.53 % | 2.42 % | 0.11 bp | 2.46 % | 2.03 % | 0.43 bp | 2.32 % | 2.07 % | 0.25 bp | ||
Forward looking statement:
This press release published by ADAMA Ltd. or ADAMA Agricultural Solutions Ltd. (together the "Company") is for marketing and information purposes only, and contains forward-looking statements which are based on Company's management's beliefs and assumptions and on information currently available to the Company's management. By this press release, the Company does not intend to give, and the press release does not constitute, professional or business advice or an offer or recommendation to perform any transaction in the Company's securities. The accuracy, completeness and/or adequacy of the content of this press release, as well as any estimation and/or assessment included in this press release, if at all, is not warranted or guaranteed and the Company disclaims any intention and/or obligation to comply with such content. The Company shall not be liable for any loss, claim, liability or damage of any kind resulting from your reliance on, or reference to, any detail, fact or opinion presented herein. The Company's assessments are based on the information available to the Company as of the date hereof, and may not be realized or be realized in a different manner than the Company estimates, inter alia, due to factors out of the Company's control, including the risk factors listed in the Company's annual reports and changes in the industry or potential operations of the Company's competitors. Any content contained herein shall not constitute or be construed as any regulatory, valuation, legal, tax, accounting and investment advice or any advice of any kind or any part of it, nor shall they constitute or be construed as any recommendation, solicitation, offer or commitment (or any part of it) to buy, sell, subscribe for or underwrite any securities, provide any credit or insurance or engage in any transactions. Before entering into any transactions, you shall ensure that you fully understand the potential risks and returns of such transactions. Before making such decisions, you shall consult the advisors you think necessary, including your accountant, investment advisor and legal and tax specialists. The Company and its affiliates, controlling persons, directors, officials, partners, employees, agents, representatives or their advisors shall not assume any responsibilities of any kind (including negligence or others) for the use of and reliance on such information by you or any person to whom such information are provided.
[1.] CER – Constant Exchange Rates
[2.] Sources: Agbio Investor preliminary 2023 market estimation, CCPIA (China Crop Protection Industry Association), peer quarterly financial reports, internal sources
[3.] For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".
[4.] The number of shares used to calculate both basic and diluted earnings per share in both Q4 2023 and 2022 is 2,329.8 million shares.
[5.] For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".
[6.] The number of shares used to calculate both basic and diluted earnings per share in FY 2023 and 2022 is 2,329.8 million shares.
Logo: https://mma.prnewswire.com/media/799829/Adama_Agricultural_Solutions_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/adama-reports-fourth-quarter-and-full-year-2023-results-302099842.html
SOURCE ADAMA Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James cuts airline estimates on higher fuel, upgrades Allegiant
- Bird&Be Named Top Prenatal by Consumer Reports for the Second Time -- One of Only Two Brands Who Passed Testing
- Tenera Care and ALIS Advance Partnership with Phase II Integration
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, Dividend, Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share